Esco Lifesciences has raised $200 million in a series A and crossover round co-led by Novo Holdings and Vivo Capital. The Singapore-based company will use the cash to establish a hub for cell and gene therapy tools and technologies in Boston while expanding in China and making bolt-on acquisitions.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,